Short Interest in Pieris Pharmaceuticals Inc (PIRS) Expands By 92.8%
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) was the recipient of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 1,613,815 shares, a growth of 92.8% from the January 31st total of 836,913 shares. Based on an average daily volume of 1,488,644 shares, the days-to-cover ratio is currently 1.1 days. Approximately 3.7% of the shares of the stock are sold short.
In other news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $7.35, for a total transaction of $12,565,707.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 1,865,152 shares of company stock worth $13,478,142 over the last quarter. Corporate insiders own 4.05% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vident Investment Advisory LLC bought a new position in Pieris Pharmaceuticals during the 4th quarter worth approximately $1,590,000. Millennium Management LLC grew its position in shares of Pieris Pharmaceuticals by 57.9% in the 4th quarter. Millennium Management LLC now owns 699,771 shares of the biotechnology company’s stock worth $5,283,000 after buying an additional 256,622 shares during the last quarter. TIAA CREF Investment Management LLC grew its position in shares of Pieris Pharmaceuticals by 25.1% in the 4th quarter. TIAA CREF Investment Management LLC now owns 272,287 shares of the biotechnology company’s stock worth $2,056,000 after buying an additional 54,710 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Pieris Pharmaceuticals in the 4th quarter worth approximately $734,000. Finally, Two Sigma Advisers LP bought a new stake in shares of Pieris Pharmaceuticals in the 4th quarter worth approximately $294,000. Institutional investors and hedge funds own 52.16% of the company’s stock.
Pieris Pharmaceuticals (NASDAQ PIRS) opened at $8.35 on Friday. Pieris Pharmaceuticals has a 1 year low of $2.15 and a 1 year high of $9.75. The stock has a market capitalization of $426.24, a P/E ratio of -11.28 and a beta of 1.50.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.